Chrom Pawel, Stec Rafal, Bodnar Lubomir, Szczylik Cezary
Department of Oncology, Military Institute of Medicine, Warsaw, Poland
Department of Oncology, Military Institute of Medicine, Warsaw, Poland.
Anticancer Res. 2018 Jan;38(1):359-365. doi: 10.21873/anticanres.12230.
The study aimed to define the true impact of pancreatic metastases (PM) from renal cell carcinoma on overall survival (OS) in patients treated with first-line tyrosine kinase inhibitors.
Overall, 321 consecutive patients were analysed. The influence of PM on OS was assessed using the Kaplan-Meier estimator and the log-rank test (unadjusted and adjusted) and two multivariabe Cox proportional hazards regressions (CPHR).
Thirty-four patients (10%) had PM and 287 (90%) had sites of metastasis other than the pancreas; the median OS was 46.1 and 23.1 months, respectively (unadjusted log-rank p=0.020; adjusted log-rank p=0.544). The PM status was an insignificant factor for OS in both CPHR (hazard ratio(HR)=0.84, p=0.603, and HR=0.66, p=0.098).
The presence of PM was not an independent prognostic factor, but was rather an indicator of an indolent course of the disease.
本研究旨在明确肾细胞癌胰腺转移（PM）对接受一线酪氨酸激酶抑制剂治疗患者总生存期（OS）的真实影响。
共分析了321例连续患者。使用Kaplan-Meier估计法和对数秩检验（未调整和调整）以及两个多变量Cox比例风险回归（CPHR）评估PM对OS的影响。
34例患者（10%）发生PM，287例患者（90%）有胰腺以外的转移部位；中位OS分别为46.1个月和23.1个月（未调整对数秩p=0.020；调整对数秩p=0.544）。在两个CPHR中，PM状态对OS均为非显著因素（风险比[HR]=0.84，p=0.603；HR=0.66，p=0.098）。
PM的存在并非独立的预后因素，而是疾病进展缓慢的一个指标。
